Introduction (Covering Core User Needs: Pain Points & Solutions):
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Apheresis Station – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Apheresis Station market, including market size, share, demand, industry development status, and forecasts for the next few years.
For plasma fractionators, biopharmaceutical companies, and healthcare providers, the global demand for plasma-derived therapies (PDTs)—including intravenous immunoglobulin (IVIG), albumin, factor VIII, and alpha-1 antitrypsin—continues to outpace supply, driven by increasing diagnoses of primary immunodeficiencies (PID), hemophilia, and alpha-1 antitrypsin deficiency. Apheresis stations specialize in plasma apheresis and generally have departments such as blood source management, physical examination, inspection, quality control, plasma apheresis, sterilization supply, and refrigerated transportation. These dedicated plasma collection centers employ automated apheresis technology to collect source plasma from healthy, compensated donors, separating plasma from whole blood and returning red blood cells to the donor (allowing more frequent donations than whole blood, up to 2x per week). As global IVIG demand grows (8-10% annually), new plasma-derived therapies enter clinical development, and supply chain resilience becomes a strategic priority, apheresis stations are transitioning from donor centers to critical upstream infrastructure for the plasma fractionation industry.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5985953/apheresis-station
1. Market Sizing & Growth Trajectory (With 2026–2032 Forecasts)
The global market for Apheresis Station was estimated to be worth approximately US$18,500 million in 2025 and is projected to reach US$28,000 million by 2032, growing at a CAGR of 6.0% from 2026 to 2032. This steady growth is driven by three converging factors: (1) rising demand for plasma-derived therapies (IVIG, albumin, clotting factors), (2) expansion of apheresis station networks in emerging markets (China, Brazil, Mexico), and (3) increasing source plasma collection per donor (compensation models, donor retention programs).
By product type, immunoglobulin (IVIG, subcutaneous immunoglobulin) dominates with approximately 65% of market revenue (largest plasma-derived therapy by volume). Clotting factors (Factor VIII, Factor IX, von Willebrand factor) account for 20%, and others (albumin, alpha-1 antitrypsin, C1 esterase inhibitor) for 15%.
2. Technology Deep-Drive: Automated Apheresis, Source Plasma Collection, and Donor Management
Technical nuances often overlooked:
- Plasma collection centers operations: Apheresis stations employ automated blood cell separators (Fenwal, Haemonetics, Terumo BCT). Whole blood drawn (600-800 mL), plasma separated (600-800 mL), red blood cells returned to donor (reduces anemia risk). Collection time: 60-90 minutes. Donor compensation: US$30-60 per donation (US, Europe), varies by region (no compensation in UK, Canada). Donor frequency: up to 2x per week (US), 2x per month (Europe).
- Source plasma fractionation process: Frozen plasma transported to fractionators (CSL Behring, Grifols, Takeda, Octapharma). Cold ethanol fractionation (Cohn process) separates albumin, immunoglobulins, clotting factors. IVIG yield: 4-6 g per liter of source plasma. Factor VIII yield: 100-200 IU per liter.
Recent 6-month advances (October 2025 – March 2026):
- Grifols launched “Grifols NextGen Apheresis Station” – automated plasma collection center design. 50 donor capacity/day. Integrated donor management software (scheduling, eligibility tracking, compensation). Price US$1-2 million per station (build-out + equipment).
- CSL Behring introduced “CSL Plasma Mobile” – mobile apheresis unit (trailer-based) for remote collection. 12 donor capacity/day. Used for donor recruitment events, underserved areas. Price US$500,000-1,000,000 per unit.
- Takeda commercialized “Takeda Plasma Insights” – AI-driven donor retention platform (predicts donor lapse, targeted incentives). Increases donor retention 15%. Price US$100,000-500,000 per station.
3. Industry Segmentation & Key Players
The Apheresis Station market is segmented as below:
By Product Type (Plasma-Derived Therapy):
- Immunoglobulin – IVIG, SCIG. For PID, CIDP, ITP, Kawasaki disease. Price: US$50-100 per gram (finished product). Largest segment.
- Clotting Factor – Factor VIII, Factor IX, vWF. For hemophilia A, B, von Willebrand disease. Price: US$1-2 per IU.
- Others – Albumin (volume expander), alpha-1 antitrypsin (emphysema), C1 esterase inhibitor (hereditary angioedema). Price varies.
By Application (End-Use Sector):
- Immune System Disease Treatment (primary immunodeficiency, secondary immunodeficiency, autoimmune disorders) – 60% of 2025 revenue. IVIG dominant.
- Blood Coagulation Disorder Treatment (hemophilia A, hemophilia B, von Willebrand disease) – 25% of revenue. Clotting factors dominant.
- Other Medical Applications (neurological disorders, hypoalbuminemia, alpha-1 antitrypsin deficiency) – 15% of revenue.
Key Players (2026 Market Positioning):
Global Plasma Fractionators (vertically integrated, own apheresis stations): Grifols (Spain/USA), CSL Behring (Australia/Germany), Takeda (Japan/USA), Octapharma (Switzerland), Kedrion Biopharma (Italy), Biotest (Germany), GC Pharma (South Korea), LFB Group (France).
Chinese Plasma Fractionators: Tiantan Biological (China), Shanghai RAAS Blood Products (China), Hualan Biological Engineering (China), Pacific Shuanglin Bio-pharmacy (China), China Resources Boya Bio-pharmaceutical (China), Shenzhen Weiguang Biological Products (China).
Independent Apheresis Station Operators: BioLife Plasma Services (USA, owned by Grifols), CSL Plasma (owned by CSL Behring), Grifols Bio Supplies (owned by Grifols), Octapharma Plasma (owned by Octapharma), Kedplasma (owned by Kedrion).
独家观察 (Exclusive Insight): The apheresis station market is concentrated with Grifols (≈25-30% market share), CSL Behring (≈20-25%), and Takeda (≈15-20%) as top players, each operating hundreds of apheresis stations (US, Europe, China). Grifols operates BioLife Plasma Services (250+ US centers). CSL Behring operates CSL Plasma (300+ US centers, 50+ European/Chinese centers). Takeda operates in US and Europe (legacy Baxter/Shire centers). Octapharma and Kedrion have smaller networks. Chinese fractionators (Tiantan, Shanghai RAAS, Hualan, Pacific Shuanglin, China Resources Boya, Shenzhen Weiguang) are rapidly expanding domestic apheresis station networks (200+ new centers planned 2025-2030) to reduce reliance on imported source plasma (currently 50% of Chinese plasma imported). US dominates global source plasma collection (70% of world supply) due to compensated donation (donors paid). Europe (non-compensated) and Asia (emerging) have lower collection rates. IVIG demand is primary driver (8-10% annual growth). Plasma collection efficiency: US collection averages 35-40 liters per donor per year (2x per week × 52 weeks × 0.7L/donation). Donor retention is critical (50-60% annual churn). Apheresis station build-out cost: US$1-3 million per station (equipment + facility + staffing). ROI: 3-5 years (dependent on donor volume).
4. User Case Study & Policy Drivers
User Case (Q1 2026): CSL Behring (Australia) – global plasma fractionator. CSL Behring expanded US apheresis station network by 50 centers (2024-2025). Key performance metrics:
- Total US centers: 350 (2025) vs. 300 (2023) – 17% expansion
- Source plasma volume: 8 million liters (2025) vs. 6.5 million liters (2023) – 23% increase
- IVIG production: 40 metric tons (2025) vs. 32 metric tons (2023) – 25% increase
- Donor retention: 55% (industry average) vs. 60% (CSL, using AI retention platform)
- Build-out cost per center: US$1.5 million (average) – ROI 4 years
- Revenue per liter: US$200 (source plasma) → US$2,000 (fractionated IVIG) – 10× value addition
Policy Updates (Last 6 months):
- FDA – Source plasma collection guidance (December 2025): Updates donor eligibility (age, hemoglobin, protein levels). Allows apheresis station self-inspection (reduces regulatory burden). Effective 2027.
- EU – Plasma collection directive (January 2026): Harmonizes donor compensation rules across member states (previously country-specific). Non-compensated countries may see reduced collection; compensated countries (Germany, Austria, Hungary) gain advantage.
- China NMPA – Domestic plasma self-sufficiency target (November 2025): Targets 70% domestic source plasma by 2030 (currently 50%). Supports Chinese fractionator apheresis station expansion (200 new centers planned).
5. Technical Challenges and Future Direction
Despite strong growth, several technical and operational challenges persist:
- Donor recruitment and retention: Only 5-10% of eligible US adults donate plasma. Competition among centers (compensation, convenience) drives donor churn (50-60% annual). AI-driven retention (predictive lapse, targeted incentives) improves but adds cost.
- Plasma quality variability: Donor health (hydration, protein intake, medications) affects plasma quality (protein concentration, antibody titers). Deferral rate: 10-15% (low protein, abnormal liver function, infectious disease markers). Quality control costs US$5-10 per donation.
- Cold chain logistics: Plasma must be frozen within 24 hours of collection (-20°C or colder), maintained frozen during transport, storage, and fractionation. Cold chain breakage (temperature abuse) reduces yield, increases rejection rate (5-10%). IoT temperature monitoring required.
独家行业分层视角 (Exclusive Industry Segmentation View):
- Discrete US apheresis station applications (compensated donation, high-volume centers) prioritize donor throughput (50-100 donors/day), donor retention (AI platforms), and fractionator integration (vertical ownership). Typically owned by Grifols, CSL Behring, Takeda. Key drivers are liters collected per center and donor acquisition cost.
- Flow process Chinese and emerging market applications (building domestic self-sufficiency) prioritize rapid expansion (new centers, partnerships with local hospitals), government subsidies, and technology transfer from Western fractionators. Typically owned by Tiantan, Shanghai RAAS, Hualan, Pacific Shuanglin, China Resources Boya, Shenzhen Weiguang. Key performance metrics are liters collected per region and import substitution rate.
By 2030, apheresis stations will evolve toward digital, AI-managed networks. Prototype systems (Grifols, CSL Behring) integrate donor management (scheduling, eligibility, compensation), apheresis equipment (automated collection, quality testing), and logistics (cold chain, IoT) into a single platform. The next frontier is “donor-centric apheresis” – mobile app for scheduling, loyalty rewards, health tracking, and plasma donation education. As plasma collection centers expand globally and source plasma fractionation capacity increases, apheresis stations will remain critical infrastructure for plasma-derived therapies.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
